Article and Video CATEGORIES
Yesterday, as described in a press release, the FDA approved the regimen of cisplatin and alimta as a first line therapy for advanced NSCLC, based on the positive results from a trial called "JMDB" by the sponsor company (Eli Lilly). I described the highlights in a prior post, also recently published (abstract here). It compared cisplatin/gemcitabine to cisplatin/alimta (pemetrexed) in 1725 patients with previously untreated advanced NSCLC and found that the overall efficacy was the same between the two regimens, with a little more favorable side effect profile on the alimta arm. That wasn't the interesting part.
The part that generated interest within the lung cancer community was the fact that the different main subtypes of NSCLC (tumor histology) did better with one chemo regimen or the other. Patients with squamous NSCLC did better on cisplatin/gemcitabine, while the patients with adenocarcinoma or large cell NSCLC did better on cisplatin/alimta, as shown in both the survival curves and the table below:
Based on these results, the FDA approved the combination of cisplatin and alimta as a first line therapy, for patients with non-squamous NSCLC only. In addition, based on these findings and other work (see prior post), the FDA also amended the current approval of alimta as a second line therapy to only include treatment for patients with non-squamous NSCLC.
This is particularly important because up until very recently, there was no reason to suspect that alimta wasn't useful for the broader population of patients with advanced NSCLC, squamous and non-squamous alike. But I've done a series of lectures for general oncologists over the last couple of months, preceded by a series of case-based questions about how they would manage certain clinical situations, and it's been clear that only a minority of practicing oncologists are aware of the now compelling evidence that alimta is simply not an effective treatment for squamous NSCLC (it didn't beat placebo in a recent trial), while its activity is particularly pronounced for non-squamous NSCLC, where all of its previously noted activity appears to be concentrated.
The other important factor is that, along with the histology-specific results with avastin, there's more evidence that we need to tailor our treatments for patients by keeping their NSCLC subtype in mind. This means that we need to get enough tumor tissue at the time of biopsy to clarify the subtype. We are entering an era where our treatments for lung cancer now need to be individualized.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi Bluebird, Welcome to GRACE. I'm sorry you're going through this scare and hope it's just inflammation or from an infection you didn't know you had.
A CT would be...
Radiation + Brain Operation has just been discarded due to high risk. They will double Tagrisso dosis and then wait to see if it works, then try traditional Chemo. I would...
Hi and welcome to GRACE. I'm sorry to know you are entering a new stage. I'm not about to comment just now but wanted to let you know I see your...
Edit to say, we can't give advice but we can comment with views and facts. :)
My first thought is to ask if she has been seen at a large...
Hi Barbro, Welcome to GRACE. I'm sorry you're worrying about this. We aren't able to give feedback on scan reports. Interpreting scan reports in this setting is not only unethical but...
Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...